NT5E and triple-negative breast carcinoma: CD73 should be further evaluated as a potential biomarker of clinical benefit in studies evaluating adenosine-pathway blocking agents in various combinations, including ongoing studies in PDAC, CRC, NSCLC, and triple-negative breast cancer.